Endo, Novartis begin agreement

Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel (diclofenac sodium topical gel) 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May with an additional 275 contract sales reps targeting primary care physicians who prescribe both NSAIDs and Cox-2s.

Voltaren Gel received FDA approval in October 2007. Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions